12
Participants
Start Date
June 10, 2018
Primary Completion Date
December 31, 2021
Study Completion Date
December 31, 2021
non intervational
Subjects who completed ApoGraft-01 study (through 180 days post-transplantation) and have signed informed consent for this follow-up study will be eligible to enroll. Subject will attend 4 in-clinic visits, once every 6 months up to 2 years post transplantation, and will undergo the following evaluations: acute and chronic graft versus host disease (GvHD) assessments, survival status (overall, relapse-free), disease status (disease relapse/recurrence)
RECRUITING
Rambam Medical Center, Haifa
Lead Sponsor
Cellect Biotechnology
INDUSTRY